Cite
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
MLA
Connolly, Roisin M., et al. “Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 7, Apr. 2024, pp. 1273–80. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-23-0633.
APA
Connolly, R. M., Wang, V., Hyman, D. M., Grivas, P., Mitchell, E. P., Wright, J. J., Sharon, E., Gray, R. J., McShane, L. M., Rubinstein, L. V., Patton, D. R., Williams, P. M., Hamilton, S. R., Wang, J., Wisinski, K. B., Tricoli, J. V., Conley, B. A., Harris, L. N., Arteaga, C. L., … Flaherty, K. T. (2024). Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 30(7), 1273–1280. https://doi.org/10.1158/1078-0432.CCR-23-0633
Chicago
Connolly, Roisin M, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, et al. 2024. “Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30 (7): 1273–80. doi:10.1158/1078-0432.CCR-23-0633.